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The steady world-wide increase in the number of severely immunocompromised patients in most hospitals has 
made the control and prevention of nosocomial systemic hngal infections a critical quality-of-care standard. 
Early diagnosis and antifungal prophylaxis of these infections are complicated, so avoiding the acquisition of 
the pathogen in the case of Aspergillus and minimizing the predisposing risk factors in the case of Candida are 
more effective approaches. The maintenance of good air quality in critical areas in hospitals is mandatory to 
reduce the incidence of invasive aspergdlosis. We review the currently available Center for Disease Control 
recommendations and report our own experiences in the field. The indications and problems of fungal 
environmental and patient surveillance are also dwussed. 
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INTROOUCTION 
In recent years there has been an inexorable increase in the 
number of highly immunocompromised patients in hospital 
environments [ 1-51, Severe and prolonged neutropenia 
following chemotherapy is a major risk factor for systemic 
fungal infections [4,6,7]. However, the proportion of patients 
without neutropenia or severe immunosuppression also at risk 
of invasive fungal infections is hgher than is usually thought 
Mortality associated with disseminated fungal infection 
remains elevated [5], probably owing to the difficulties of an 
early diagnosis. Clinical and laboratory diagnosis of these 
infections lacks sensitivity and specificity [5]. Several new 
approaches to prevention and diagnosis are being developed, 
such as the monitoring of Aspergillus antigenemia. Patients 
with presumed fungal infection require intense clinical and 
laboratory monitoring for signs of disseminated infection [4]. 
Early diagnosis may guide appropriate treatment and prevent 
mortality. However, decision analysis models are needed to 
minimize the number of diagnostic tests that are used to reach 
a final diagnosis in each group of at-risk patients. It is also 
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necessary to establish whether to or not treat, given a set of 
clinical, radiological and laboratory results 1141. 
Prevention of nosocomial fungal infections is also proble- 
matic. Efforts may be addressed to prevent acquisition of 
the infection or treatment of the pathogen before it causes 
disease. In either case, implementation of preventive measures 
is costly, disruptive and involves diverse groups of hospital 
personnel. These experiences have led some experts to ask 
whether the prevention of these infections is even a realistic 
aim [15]. 
ETIOLOGY OF NOSOCOMIAL FUNGAL INFECTIONS 
The rate of nosocomial fungal infections was 2.0 per 1000 
discharges in USA in 1980 and 3.8 per 1000 discharges in 1990 
[16]. It is estimated that t h s  figure has risen since 1990, but 
there are no updated global reports. 
The majority of nosocomial fungal infections (almost 80%) 
are caused by Candida spp. [16]. They are responsible for over 
5% of a l l  nosocomial infections [17]. Candida is the fourth 
nosocomial bloodstream micro-organism. Bloodstream infec- 
tion with Candida this pathogen has the highest associated 
crude mortahty (4060%) [5,18]. 
Candida albicans ranks seventh among all hospital pathogens 
[5]. The fraction of infections caused by non-albicans Candida 
species is increasing; at present; almost 50% of bloodstream 
infections in surgcal and neonatal intensive care units are 
caused by non-albicans Candida 1181. 
Aspergillus spp. is responsible for 1.3% of fungal nosocomial 
infections [16]. None the less, the incidence appears to be 
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much higher in specialized care wards, such as in bone marrow 
transplant units [5]. 
Immunocompromised patients are hghly susceptible to 
infections by organisms of ‘low virulence’, and newly 
recognized pathogens are continuously being reported, such 
as Malassezia spp., Fusarium spp., Trichosporon spp., Mucor spp., 
Paecilornyces lilacinus, Pseudallescheria boydii, Scedosporium prol$- 
cans, Hansenula anomala and Blastoschizornyces capitatus [ 19-27]. 
SOURCES OF INFECTION 
The modes of transmission and portals of entry of fungal 
nosocomial infections vary according to the pathogen involved. 
Candida is predominantly of endogenous origin but cross- 
infection via the hands of health-care workers or relatives or 
through different devices has been shown to occur [5]. 
Aspergillus causing clinical dsease is usually acquired from 
outside, mainly through the respiratory tract or through direct 
inoculation (such as postoperative wounds, heart valves, etc.). 
Acquisition of less eequent fungal infections may be 
endogenous, or related to hand carried or airborne fungi, or 
to previous tissue trauma, etc. In these infections, increased 
host susceptibility is thought to be the primary risk factor 
PREVENTIVE MEASURES 
Avoid acquisition from the environment 
Air quality maintenance 
The maintenance of good quality air in hospital contributes 
substantially to reduce the incidence of invasive aspergillosis. 
Aspergdlus is ubiquitous in the external environment and 
numerous reservoirs have also been identified in hospitals: 
unfiltered air, ventilation systems, contaminated dust during 
hospital construction, carpeting, water food and ornamental 
plants [ 1,2,5,9,28]. 
Most patients with invasive aspergillosis (IA) present with 
pneumonia; therefore, it has been hypothesized that the 
inhalation of airborne spores, either directly or after 
intermediate nasopharyngeal colonization, is a direct cause of 
pulmonary infection in immunocommpromised patients 151. 
The concentration of Aspergillus spores in the hospital air is 
the major extrinsic risk factor for the occurrence of 
nosocomial IA [2,5,28,29]. Therefore, the most obvious 
strategy to reduce IA is to diminish exposure of immuno- 
compromised patients to Aspegillus conidia by using environ- 
mental control. 
Environmental strategies are recommended for high-risk 
areas (bone marrow transplantation units, surgical rooms, etc.). 
Table 1 shows the Center for Disease Control (CDC) 
recommendations [28]. They include the use ofthe following: 
high-efficiency particulate air (HEPA) filtration of incom- 
ing air; 
directed room airflow; 
positive room-air pressure relative to the corridor; 
well-sealed rooms; 
high rates of room air changes. 
The integnty of the air filtration system needs to be closely 
monitored with regular, planned preventive maintenance, 
spore counting, pressure monitoring and airflow changes 
[1,5,28]. In our experience, the practice of routinely under- 
taking air surveillance has been essential in the detection of 
failures in the system. 
The use of HEPA filtration [lo] and of laminar airflow [6,8] 
in high-risk units has been shown to reduce the risk of IA but 
does not reduce it to zero. The reasons for this apparent failure 
include the fact that some of the patients may already be 
colonized by Aspergillus when they enter hospital, or because 
patients leave protective environments to undergo diagnostic 
or therapeutic procedures [3,6]. Of course, a real leak in 
airflow must also be considered. 
CDC guidelines recommend that hospital policies to 
minimize exposure of high-risk patients to potential sources 
of Aspergiltus, such as hospital construction and renovation, 
cleaning activities, carpets, food, potted plants and flower 
arrangements, should be put into practice [28]. 
In facilities with no previous case of aspergdlosis, dust 
accumulation should be prevented by dady damp-dusting 
horizontal surfaces and regularly cleaning ceiling and air-duct 
g n l l s  when the rooms are not occupied by patients [1,2,28]. 
Systematic review and coordination of infection control 
strategies with hospital personnel in charge of engineering, 
maintenance and catering should be undertaken. 
When hospital construction and renovation activities are 
being planned, a strategy should be implemented to prevent 
patients at high risk of aspergdlosis from exposure to high 
spore levels in the air. Impermeable barriers must be 
constructed between patient-care and construction areas to 
prevent dust from entering patient-care areas. Maintenance of 
a negative pressure in areas relative to adjacent patient-care 
areas is essential unless there are contraindications for such 
pressure differentials. Direction of pedestrian traffic away from 
con-struction areas prevents dust dispersion. A x  and environ- 
mental monitoring for fungal spores may be indxated 
when building works adjacent to a hgh-dependency unit 
are taking place. 
Owing to demolition work of a building close to our 
general hospital main building (Figure 1) this year we have 
demonstrated the valihty and reliability of air sampling 
procedures before, during and after demolition (data not 
published). There was a clear elevation in the counts of 
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Table 1 Recommendations for the 
prevention and control of nosocomial 
pulmonary aspergillosis [28] 
Categorya Recommendation 
Staff education, especially care providers for immunocompromised patients 
Surveillance, with focus on 
High-risk patients (< 1000 granulocytes/mm3 for 14 days, 
<lo0 granulocytes/mm3 for 7 days) 
Periodic review of microbiological, histopathological and postmortem data 
Periodic surveillance cultures of high-risk patients 
New construction of specialized care unit for high-risk patients 
Minimization of fungal spore counts by HEPA filtration, directed airflow, 
positive pressure, proper seals, high rates of room-air changes 
Ultra-high air change rates (100-400/h), laminar airflow 
Minimization of exposure of high-risk patients to construction and carpet 
and floor cleaning 
Prophylactic use of copper-8-quinolinolate biocide in fireproofing material 
Existing facilities with no cases of nosocomial aspergillosis 
Minimize fungal spore counts as above 
Minimize exposures as above 
Conduct routine maintenance of the heating, ventilation, and air-conditioning 
system, including prevention of bird access to air intake ducts 
Minimize time and wear mask when high-risk patients are outside the area 
Eliminate potential Aspergillus-contaminated food, potted plants and flowers 
During construction, erect barriers, direct pedestrian traffic away and clean 
new areas before entry to  high-risk patients* 
After a case of nosocomial aspergillosis occurs 
Begin a retrospective review and prospective search of other cases 
If continuing infection occurs, conduct an environmental investigation 
Contact the local or state health department if assistance is needed 
Decrease host risk of infection 
Use of cytokines to decrease the duration of granulocytopenia 
lntranasal amphotericin B or oral antifungal agents prophylactically 
IA 
IB 
IB 
Unresolved 
IB 
Unresolved 
IB 
Unresolved 
IB 
IB 
IB 
IB 
11 
IB 
IB 
IB 
IB 
II 
Unresolved 
aCategories are as follows: IA, strongly recommended for all hospitals and supported by well- 
designed experimental or epidemiological evidence; IB, strongly recommended for all hospitals and 
viewed as effective by experts on the basis of strong rationale and suggestive evidence; II, suggested 
for implementation in many hospitals, supported by suggestive clinical or epidemiological studies 
with a strong theoretical rationale or definitive studies applicable to some but not all hospitals; 
Unresolved, practices for which insufficient evidence or consensus regarding efficacy exists. 
filamentous fungal spores linked to demolition by controlled 
explosion (Figure 2) .  The sealing of doors and windows, the 
closing of external air ducts and the continuous air renovation 
and positive pressure in the operating theaters and in areas 
with a protective environment during demolition works 
proved efficacious in avoiding an increase in spore counts. No 
cases of IA were detected in hospitalized patients. 
When a case of nosocomial aspergillosis occurs, the CDC 
recommends a prospective search for admtional cases in 
hospitalized patients and an intensified retrospective review 
of the hospital’s microbiology. Histopathology and postmor- 
tem records should also be investigated. If evidence of 
continuing Aspetgillus infection exists, then an environmental 
investigation should be conducted to determine and eliminate 
the source. 
Environmental surveillance is also recommended in the 
following situations: monthly surveillance in protected areas, 
during reformation works near hgh-risk areas, before patients 
enter a new protected area or after renovation and when there 
is suspicion of dysfunction in the quality of air systems. 
For details of the practicalities of environmental surveillance 
[30], we refer the reader to Richardon’s excellent article on 
the Aspergillus website (http : / /www. aspergdhman. ac . uk) . 
The most common method of measuring airborne conidial 
loads relies on an air filtration device. Other methods estimate 
the level of contamination by determining the number of 
conidia adhering to the walls of the patient’s room by using 
contact methods with Petri dishes or swabbing with cotton- 
coated applicator sticks. Each sampling method has its merits 
and, at present, the method most frequently used in indoor air 
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Figure 1 Cloud of dust produced the day of the controlled demolition 
of our maternity hospital. 
Fig 3 MAS-100 Air Sampler (Merck) and Sabouraud irradiated agar 
plates used in our hospital for sampling high-risk areas. 
Figure 2 Agar plates with filamentous fungi obtained by sampling 
hospital air with an air filtration device. 
surveys is impacting particles &om an airstream onto an agar 
surface (Figure 3). 
Unfiltered air averages 1-1 5 pathogenic Aspergillus spp. 
colony-forming units (CFU) per m3, although short-term 
variations (such as seasonal variations) are substantial [31]. 
Although there is no reasonable estimation of a threshold of 
conidial concentration above which the risk of IA increases 
[4], most authors recommend Aspergillus air counts of less than 
5 CFU/m3 in the operating theater and in protective isolation 
suites, although counts of less than 0.1-1 CFU/m3 are 
desirable. There is a great variability between countries (such 
as 10-200 CFU/m3 according to the type of surgery). 
The repeated isolation of the same fungal species from 
several samples or an increase in usual counts must raise 
concern about the existence of an environmental reservoir. 
With regard to the operating theater, samples taken at the air- 
intake gnll allow evaluation of the ventilation system. Samples 
taken at the center of the theater reflect the hygienic 
conditions of the room. It is common to find counts 2-3 
times higher in these latter samples. 
When the counts are over the acceptable limits and without 
a clear cause to justify them and to act on (such as works, 
ventilation system fault, etc.), the first action to take is to 
confirm the environmental sampling results. Ths is because 
any movement close to the sampling area, such as an air 
draught, may cause false-positive results. If the high count 
should persist, then the operating theatre or isolation ward will 
be closed. The hygienic condition of the airflow tubes and of 
the gnlls in the ventilation system must then be checked by the 
maintenance staff, as well as the correct technical performance 
of the system and the last change of filters. 
Routine environmental sampling allows determination of 
reference air contamination limits to be used in every-day 
practice. With the routine use of the same method, its 
reliability and cost-effectiveness are guaranteed. However, the 
cost of investigating an outbreak of Aspergillusflavus in an 
operating room, just on environmental samples, may be high. 
It is important to remember that genetic analysis cannot 
discriminate between clinical and environmental isolates of A. 
fumigatur, indicating that every strain present in the environ- 
ment is a potential pathogen if it encounters the appropriate 
host [32]. Thus, the degree of exposure assessed by CFUs per 
unit of ambient air is not predictive of disease; the actual risk 
appears to vary with the underlying condition. 
At present, only three methods can be used for genotypical 
typing of A.  fumigatus strains [4]. Although most researchers 
have used the PCR- and RFLP-based typing methods 
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separately, studies are under way to compare their d~scrimi- 
natory potential and to evaluate if combination of data 
obtained by more than one typing method will lead to better 
strain discrimination [4,33]. To date, strain typing has been 
most successful by microsatellite polymorphism or analysis of 
Southern hybridization patterns obtained with repeated DNA 
sequences [4]. 
The results of fingerprinting clinical isolates &om multiple 
sites in a given patient with aspergdoma or IA indicate that, in 
most cases, the infection is caused by a single strain [32,34-361. 
However, in certain patients, tested under conmtions which 
excluded the possibility of accidental contamination of 
biological samples, two strains were isolated, suggesting that 
mixed infections with different strains of A.  fumigutus can 
occur in IA [4]. 
In a confined area such as a hospital, airborne conidia are 
extremely diverse, with 85% of the strains being isolated only 
once and each displaying a unique fingerprinting pattern [4]. 
The remaining 15% of the strains, which account for over 30% 
of the isolates, may each be isolated on several occasions, and 
may persist for several months in the same hospital environ- 
ment [4]. This suggests that the majority of strains isolated are 
specific to each hospital and originate less commonly from the 
local outside environment. 
If the isolation of the same fungal strain from the patient and 
the environment is the criterion used for ‘hospital-acquired 
infection’, then some 3040% of the cases of IA are 
nosocomial [4,8,37]. However, even during outbreaks of 
aspergdlosis, multiple patients are rarely infected by the same 
strain [34]. Each patient is surrounded by an extremely diverse 
population of strains. Furthermore, the absence of identity 
between genotypes found in patient-associated fungi and fungi 
found in their environment should not exclude a nosocomial 
origin of an infection [4]. The nosocomial nature of IA can be 
demonstrated even after several weeks of delay between 
acquisition of the fungus and the development of IA. 
In summary, we believe that environmental sampling is a 
usehl tool for determining the presence of a problem with the 
quality of the air in the hospital setting. However, its results 
must be interpreted with caution. 
Water 
Opportunistic fungal pathogens have been recovered from 
sinks and shower heads in several hospitals in the USA. A.  
teneus and A.  nigev were cultured from the shower heads, as 
well as Fusarium spp. Sampling before and after showering 
revealed a significant increase in spore counts in the air. The 
clinical significance of this finding remains unclear. A.  
fumigutus, which is by fir the most frequent causative pathogen 
of IA, has not been recovered from water in any hospital in the 
USA, but it has been found in tapwater samples in a 
Norwegian hospital [38]. Some authorities feel that mould 
proliferation around sink outlets may represent another 
environmental reservoir, so water leaks should be cleaned up 
and repaired [2,8]. Nevertheless, the role of water in the 
transmission of aspergdh needs further elucidation. 
Cross- transmission 
Cross-transmission of filamentous fungi is very rare, although 
there are some reports. Fomites have been found to be the source 
of aspergdh in an outbreak of cutaneous aspergdo& [39]. Other 
sources identified include contaminated substance abuse material 
mjected intravenously or contaminated cannabis [l]. 
Cundida may be transmitted after contact with colomzed 
health-care workers or patients’ relatives (hands or orophar- 
yngeal colonization). Meticulous handwashing or disinfechon 
is the best preventive measure of cross-infection by Cundida. 
PROMPC OIAGNOSIG 
Surveillance cultures 
Fungal surveillance cultures have been studied as potential 
predictors of invasive or disseminated mycoses. Active 
surveillance of patients considered to be at high risk for fungal 
infection has enhanced case detection in some instances 
[37,40] and this is the main reason for its advisability. 
Surveillance cultures of AspergiIIus are indicated in a very 
specific set of patients. These include selected groups of 
transplant patients (solid organ transplant (SOT) and bone 
marrow transplant (BMT)), granulocytopenic patients (such as 
those with malignancies) and selected groups of HIV-positive 
patients [41]. The criteria used for indicating the performance 
of surveillance cultures are usually based on the presence of 
risk factors for invasive mycosis, such as the need for 
hemodyahsis after a solid organ transplantation or very low 
CDA counts in the case of HIV-infected patients. 
Sputum cultures positive for Aspergillus have different 
sensitivities for the diagnosis of invasive respiratory aspergd- 
losis. They range from 72% in patients with hematological 
malignancies, BMT or granulocytopenia, and 58% in SOT to 
14% in HIV-positive patients [42,43]. Sensitivity also depends 
on the species isolated [43]. The sensitivity is as h g h  as 98% if 
Aspergillusfurnigutur is isolated from a respiratory sample in a 
heart transplant patient [43]. 
Sputum cultures also have different positive predictive 
values regardmg the type of SOT. They range from 60% to 
82%, 56%, 41-72%, 3 0 4 5 %  and 16% in bone marrow, heart, 
liver, hdney and lung transplants respectively [44]. These have 
also shown a good positive predictive value in leukemic 
patients during an outbreak [45]. Nevertheless, diagnosis of 
invasive disease using this method will be too late to aid in the 
clinical management of the patients. 
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Fungal survelllance cultures in BMT have shown that 
colonization is not necessarily predictive of hngal infection 
but may prompt more aggressive diagnosis or early treatment 
of potentially fatal invasive infections [29]. Routine nasal 
cultures have been recommended before transplantation, in 
cases of neutropenia longer than 7 days or in neutropenic 
patients with fever [45,46]. In some studies, samples taken 
from the tongue and perineum have shown colonization more 
often than those taken from the nostrils [29]. However, 
cultures from these sites are not of proven value as indicators of 
prophylaxis [47]. 
Regarding Cundidu, previous colonization is the most 
important independent risk factor for the development of 
invasive disease [5,40,48,49]. Very few patients have hngemia 
without a prior positive culture. 
In several stuhes, fungal colonization of two or more 
noncontiguous anatomical sites correlates with an increase in 
the mortality risk of dmeminated candidiasis (even higher than 
with fungemia) [48,50-521. This is why, in every patient with 
clinically suspected candidiasis (symptomatic) or simply with 
multiple risk factors, it is advisable to obtain samples from the 
upper respiratory tract (pharynx and lung secretions), drains, 
s u r g d  wounds, urine, gastric fluid, the skin around every 
intravascular catheter, blood and even feces (for a direct 
examination). It is important to detect this multiple colonization, 
because it usually precedes the onset of the systemic illness caused 
by Cundidu and, in some cases, more effective than blood cultures 
[53]. Detection of colonization by Cundidu of two or more 
noncontiguous anatomical sites in intensive care unit patients 
inmcates the need for pre-emptive therapy [54]. 
Depending on the presence or absence of symptoms and 
infection risk factors, hfferent courses of action were 
recommended by experts at a consensus conference [55]. In 
patients with symptomatic risk and even in those with no risk 
factors, they recommended surveillance cultures. The diag- 
nostic value of these cultures in asymptomatic at-risk patients 
was not established. Considering the high attributable crude 
mortality (40%) of dmeminated candidiasis in these patients, 
we believe that the possibhty of colonization by Cundidu 
should be actively investigated, as we have already mentioned. 
Apart from the number of different anatomical sites 
colonized, the type of Candidu is also very important, e.g. it 
helps to determine the specific antifungal treatment and it also 
helps to find the origin of the infection. For instance, with 
regard to the origin, we know that Cundidu purupsilosis 
fungemia suggests infection of an intravascular device; so any 
catheters should be withdrawn. Isolation of Cundidu tropicalis 
has a high positive predictive value for disseminated disease, 
and it highlrghts a group of patients needing empirical 
treatment but not prophylaxis [49]. In some series, 80-100% 
of the patients colonized with C. tropicalis develops an invasive 
infection [56]. Obviously, surveillance cultures may no longer 
be necessary if prophylaxis is administered [57]. 
This is useful in the detection of existing patient coloniza- 
tion by any type of fungus, be it a yeast or a filamentous fungus. 
This comes in usell in the investigation of outbreaks, as occurred 
in a cluster of infections with Blustoschizomyces cupitatus in the 
hematology ward in our hospital (unpublished data). 
Serodiagnosis of invasive fungal infections 
In contrast to immunocompetent hosts, growth of A.fumigutus 
in the tissues of immunodepressed hosts is not correlated with 
an increase in anti-Aspergillus antibody titers. In fact, the 
presence of anti-Aspergillus antibodies in immunocompro- 
mised individuals is more likely to represent antibody formed 
before the onset of the immunosuppressive therapy rather than 
the result of invasive infection [4]. Antibody detection in thls 
population can be used prognostically but not diagnostically 
for IA. 
In fact, the serological ctagnosis of IA is based on the 
detection of circulating antigens in b i o l o g d  fluids (such as 
serum, urine and BAL) obtained from patients. For a detailed 
review on this matter, we refer the reader to two excellent 
articles by Latge [4,14]. Briefly, the Platelia (Sanofi Diagnostic 
Pasteur) sandwich ELISA for the detection of galactomannan 
(GM) is currently the most sensitive method developed [58]. 
This test conrributes to the early diagnosis of IA, even before 
signs and symptoms of the disease become apparent (medan of 
6 days). This is its most important feature, because the 
detection of antigenemia dictates the initiation of therapy. 
Another advantage is that the decrease in GM concentration in 
serum correlates with treatment efficacy. 
The diagnosis of Cundidu by serology consists of the 
detection of mannan and antimannan antibodies [4,40]. The 
sensitivity of the test is good (85.7%), but the specificity and 
positive predctive value are low because of too many false- 
positive reactions (up to 50%). 
The sensitivity of detection in serological tests must be 
improved. New tests under study include the detection of cell 
wall markers such as galactosaminoglycan or 1,3-d-glucan and 
an immuno-PCR method for GM. 
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